Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab
Executive Summary
Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.
You may also be interested in...
Amgen’s Lumakras Efficacy Confirmed In Phase III, But Not As Strong As Phase II
Lumakras data at ESMO in KRAS G12C-mutated lung cancer bested docetaxel on PFS, and largely on safety. OS was better for chemotherapy, but the trial was not powered for statistical significance on OS.
Amgen Rebuilt R&D Platform To Focus On Speed And Access
The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs.
Lumakras Sales A Highlight Of Amgen’s Mixed Q3
While revenue beat consensus, the company slightly lowered its 2021 guidance due to pandemic impacts, but the closely watched KRAS G12C inhibitor exceeded expectations in its first full quarter.